[go: up one dir, main page]

WO2002099116A3 - Therapeutic polypeptides, nucleic acids encoding same, and methods of use - Google Patents

Therapeutic polypeptides, nucleic acids encoding same, and methods of use Download PDF

Info

Publication number
WO2002099116A3
WO2002099116A3 PCT/US2002/017428 US0217428W WO02099116A3 WO 2002099116 A3 WO2002099116 A3 WO 2002099116A3 US 0217428 W US0217428 W US 0217428W WO 02099116 A3 WO02099116 A3 WO 02099116A3
Authority
WO
WIPO (PCT)
Prior art keywords
nucleic acids
methods
acids encoding
encoding same
therapeutic polypeptides
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2002/017428
Other languages
French (fr)
Other versions
WO2002099116A2 (en
WO2002099116A8 (en
Inventor
David W Anderson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
CuraGen Corp
Original Assignee
CuraGen Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/162,335 external-priority patent/US7034132B2/en
Application filed by CuraGen Corp filed Critical CuraGen Corp
Priority to CA002448073A priority Critical patent/CA2448073A1/en
Priority to EP02739617A priority patent/EP1401858A4/en
Publication of WO2002099116A2 publication Critical patent/WO2002099116A2/en
Publication of WO2002099116A8 publication Critical patent/WO2002099116A8/en
Publication of WO2002099116A3 publication Critical patent/WO2002099116A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Disclosed herein are nucleic acid sequences that encode G-coupled protein-receptor related polypeptides. Also disclosed are polypeptides encoded by these nucleic acid sequences, and antibodies, which immunospecifically-bind to the polypeptide, as well as derivatives, variants, mutants, or fragments of the aforementioned polypeptide, polynucleotide, or antibody. The invention further discloses therapeutic, diagnostic and research methods for diagnosis, treatment, and prevention of disorders involving any one of these novel human nucleic acids and proteins.
PCT/US2002/017428 2001-06-04 2002-06-04 Therapeutic polypeptides, nucleic acids encoding same, and methods of use Ceased WO2002099116A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
CA002448073A CA2448073A1 (en) 2001-06-04 2002-06-04 Therapeutic polypeptides, nucleic acids encoding same, and methods of use
EP02739617A EP1401858A4 (en) 2001-06-04 2002-06-04 Therapeutic polypeptides, nucleic acids encoding same, and methods of use

Applications Claiming Priority (38)

Application Number Priority Date Filing Date Title
US29566101P 2001-06-04 2001-06-04
US29560701P 2001-06-04 2001-06-04
US60/295,661 2001-06-04
US60/295,607 2001-06-04
US29641801P 2001-06-06 2001-06-06
US29640401P 2001-06-06 2001-06-06
US60/296,418 2001-06-06
US60/296,404 2001-06-06
US29828501P 2001-06-14 2001-06-14
US60/298,285 2001-06-14
US29855601P 2001-06-15 2001-06-15
US60/298,556 2001-06-15
US29994901P 2001-06-21 2001-06-21
US60/299,949 2001-06-21
US30088301P 2001-06-26 2001-06-26
US60/300,883 2001-06-26
US30155001P 2001-06-28 2001-06-28
US60/301,550 2001-06-28
US31197201P 2001-08-13 2001-08-13
US60/311,972 2001-08-13
US31507101P 2001-08-27 2001-08-27
US60/315,071 2001-08-27
US31566001P 2001-08-29 2001-08-29
US60/315,660 2001-08-29
US32229301P 2001-09-14 2001-09-14
US60/322,293 2001-09-14
US32270601P 2001-09-17 2001-09-17
US60/322,706 2001-09-17
US34118601P 2001-12-14 2001-12-14
US60/341,186 2001-12-14
US36118902P 2002-02-28 2002-02-28
US60/361,189 2002-02-28
US36367602P 2002-03-12 2002-03-12
US36367302P 2002-03-12 2002-03-12
US60/363,673 2002-03-12
US60/363,676 2002-03-12
US10/162,335 US7034132B2 (en) 2001-06-04 2002-06-03 Therapeutic polypeptides, nucleic acids encoding same, and methods of use
US10/162,335 2002-06-03

Publications (3)

Publication Number Publication Date
WO2002099116A2 WO2002099116A2 (en) 2002-12-12
WO2002099116A8 WO2002099116A8 (en) 2003-09-25
WO2002099116A3 true WO2002099116A3 (en) 2003-11-20

Family

ID=28047119

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2002/017428 Ceased WO2002099116A2 (en) 2001-06-04 2002-06-04 Therapeutic polypeptides, nucleic acids encoding same, and methods of use

Country Status (3)

Country Link
EP (1) EP1401858A4 (en)
CA (1) CA2448073A1 (en)
WO (1) WO2002099116A2 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6815181B2 (en) 2001-07-09 2004-11-09 Applera Corporation Nucleic acid molecules encoding human secreted hemopexin-related proteins
EP2248899B8 (en) 2003-03-19 2015-07-15 Biogen MA Inc. NOGO receptor binding protein
EP2474317A1 (en) 2004-06-24 2012-07-11 Biogen Idec MA Inc. Treatment of conditions involving demyelination
WO2007008547A2 (en) 2005-07-08 2007-01-18 Biogen Idec Ma Inc. Sp35 antibodies and uses thereof
EP2158317B1 (en) 2007-05-16 2018-03-28 Gene Signal International Sa Anti-tumor drug, medicament, composition, and use thereof
EP1992694A1 (en) * 2007-05-16 2008-11-19 Gene Signal International Sa Anti-tumor drug, medicament, composition, and use thereof
JP2011527572A (en) 2008-07-09 2011-11-04 バイオジェン・アイデック・エムエイ・インコーポレイテッド Composition comprising a LINGO antibody or fragment
JP2015518829A (en) 2012-05-14 2015-07-06 バイオジェン・エムエイ・インコーポレイテッドＢｉｏｇｅｎ ＭＡ Ｉｎｃ． LINGO-2 antagonist for treatment of conditions involving motor neurons
AU2016205197B2 (en) 2015-01-08 2021-10-21 Biogen Ma Inc. LINGO-1 antagonists and uses for treatment of demyelinating disorders

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4446129A (en) * 1982-09-17 1984-05-01 Eisai Co., Ltd. Method for treatment of arthrosis deformans with elastase
US4643991A (en) * 1984-12-18 1987-02-17 The University Of Kentucky Research Foundation Peptide elastase inhibitors and methods
US4746729A (en) * 1986-07-30 1988-05-24 Kuettner Klaus E Cartilage-derived leukocyte elastase-inhibitor
US4968614A (en) * 1986-04-26 1990-11-06 Sankyo Company Limited Human pancreatic elastase I
US4985361A (en) * 1985-04-05 1991-01-15 Sankyo Company, Limited Human pancreatic elastase
US5212068A (en) * 1985-04-05 1993-05-18 Sankyo Company Limited Human pancreatic elastase

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001023419A2 (en) * 1999-09-27 2001-04-05 Scios Inc. Differentially expressed genes

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4446129A (en) * 1982-09-17 1984-05-01 Eisai Co., Ltd. Method for treatment of arthrosis deformans with elastase
US4643991A (en) * 1984-12-18 1987-02-17 The University Of Kentucky Research Foundation Peptide elastase inhibitors and methods
US4985361A (en) * 1985-04-05 1991-01-15 Sankyo Company, Limited Human pancreatic elastase
US5212068A (en) * 1985-04-05 1993-05-18 Sankyo Company Limited Human pancreatic elastase
US4968614A (en) * 1986-04-26 1990-11-06 Sankyo Company Limited Human pancreatic elastase I
US4746729A (en) * 1986-07-30 1988-05-24 Kuettner Klaus E Cartilage-derived leukocyte elastase-inhibitor

Also Published As

Publication number Publication date
WO2002099116A2 (en) 2002-12-12
EP1401858A2 (en) 2004-03-31
CA2448073A1 (en) 2002-12-12
EP1401858A4 (en) 2005-12-21
WO2002099116A8 (en) 2003-09-25

Similar Documents

Publication Publication Date Title
WO2002014368A8 (en) Proteins and nucleic acids encoding the same
WO2002055705A3 (en) Proteins and nucleic acids encoding same
WO2002064791A3 (en) Proteins and nucleic acids encoding same
WO2002057453A3 (en) Polypetides and nucleic acids encoding same
WO2002068649A3 (en) Proteins and nucleic acids encoding same
WO2002057450A3 (en) Proteins and nucleic acids encoding same
WO2002068652A3 (en) Nov-x proteins and nucleic acids encoding same
WO2004015060A3 (en) Therapeutic polypeptides, nucleic acids encoding same, and methods of use
WO2002081518A3 (en) Proteins, polynucleotides encoding them and methods of using the same
WO2002029058A3 (en) Human proteins, polynucleotides encoding them and methods of using the same
WO2001081578A3 (en) Novel proteins and nucleic acids encoding same
WO2002081510A3 (en) Proteins, polynucleotides encoding them and methods of using the same
WO2002016599A3 (en) Proteins and nucleic acids encoding same
WO2002046229A3 (en) Novel proteins and nucleic acids encoding same
WO2002029038A3 (en) Novel proteins and nucleic acids encoding same and antibodies directed against these proteins
WO2002055704A3 (en) Proteins, polynucleotides encoding them and methods of using the same
WO2002079398A3 (en) Therapeutic polypeptides, nucleic acids encoding same, and methods of use
WO2002010216A3 (en) Proteins and nucleic acids encoding same
WO2001074904A3 (en) G-protein coupled receptors and nucleic acids encoding same
WO2001066747A8 (en) Proteins named fctrx and nucleic acids encoding same
WO2002099116A3 (en) Therapeutic polypeptides, nucleic acids encoding same, and methods of use
WO2001074851A3 (en) Novel proteins and nucleic acids encoding same
WO2002083841A3 (en) Therapeutic polypeptides, nucleic acids encoding same, and methods of use
WO2002026826A3 (en) Proteins and nucleic acids encoding same
WO2002068647A3 (en) Proteins, polynucleotides encoding them and methods of using the same

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US US US US US US US US

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
CFP Corrected version of a pamphlet front page
CR1 Correction of entry in section i

Free format text: IN PCT GAZETTE 50/2002 UNDER (30) REPLACE "60/295,404, 6 JUNE 2001 (06.06.2001), US" BY "60/296,404, 6 JUNE 2001 (06.06.2001), US" AND 60/261,189, 28 FEBRUARY 2002 (28.02.2002), US" BY 60/361,189, 28 FEBRUARY 2002 (28.02.2002), US" AND "NOT FURNISHED" BY "10/162,335"

WWE Wipo information: entry into national phase

Ref document number: 2002312258

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2448073

Country of ref document: CA

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2002739617

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2002739617

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 2002739617

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP